Literature DB >> 405315

Tumour-associated inhibition of immediate hypersensitivity reactions in mice.

N R Lynch, J C Salomon.   

Abstract

The intensity of anaphylactic shock was lower in C3H mice carrying a methylcholanthrene-induced tumour (McC3) than in their normal counterparts when immunized with ovalbumin and challenged i.v. after 14 days. This tumour-associated inhibitory effect on active systemic anaphylaxis was exerted mainly on events occurring after homocytotropic antibody synthesis because the serum titres of these antibodies were comparable in normal and tumour-bearing animals. In addition, passive systemic anaphylactic reactions were suppressed in animals carrying the tumour and the sensitivity of these animals to challenge with histamine and serotonin mixtures was also reduced. The presence of a growing McC3 tumour did not, however, diminish the amine-sensitizing effect of treatment with Bordetella pertussis vaccine. The McC3 tumour inhibited the generation of passive cutaneous anaphylactic reactions, an effect that was also exerted by a tumour extract, particularly when administered to the recipients shortly before antigen challenge. Thus immediate hypersensitivity reactions, like a variety of other immunological processes, can be inhibited by tumour products which by compromising the immune status of the host might permit tumour growth. The nature of the inhibiting factor is unknown, except that it is probably not the amine-degrading enzyme histaminase. In addition, which it is uncertain whether the inhibitory effect is exerted directly or indirectly, the possible importance of prostaglandins in the phenomenon is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 405315      PMCID: PMC1445308     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Structural and functional characteristics of the microcirculation in neoplasms.

Authors:  J M Papadimitrou; A E Woods
Journal:  J Pathol       Date:  1975-06       Impact factor: 7.996

Review 2.  Histamine-sensitizing factors from microbial agents, with special reference to Bordetella pertussis.

Authors:  J Munoz; R K Bergman
Journal:  Bacteriol Rev       Date:  1968-06

3.  Probable role of prostaglandins in asthma.

Authors:  W Dawson; W J Sweatman
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

4.  A new histaminase assay.

Authors:  H G Roscoe; D Kupfer
Journal:  Anal Biochem       Date:  1972-06       Impact factor: 3.365

5.  Effects of neoplasms on inflammation: depression of macrophage accumulation after tumor implantation.

Authors:  R Snyderman; M C Pike; B L Blaylock; P Weinstein
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

6.  Elevated histaminase (diamine oxidase) activity in small-cell carcinoma of the lung.

Authors:  S B Baylin; M D Abeloff; K C Wieman; J W Tomford; D S Ettinger
Journal:  N Engl J Med       Date:  1975-12-18       Impact factor: 91.245

7.  Altered immunologic responsiveness in mastocytoma-bearing mice.

Authors:  I Kamo; C Patel; H Friedman
Journal:  J Natl Cancer Inst       Date:  1976-02       Impact factor: 13.506

8.  Role of the eosinophil in the allergic reactions. II. Release of prostaglandins from human eosinophilic leukocytes.

Authors:  T Hubscher
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

9.  Characterization of a T-lymphocyte inhibitor in the serum of tumour-bearing mice.

Authors:  J G Levy; A G Smith; R B Whitney; R McMaster; D G Kilburn
Journal:  Immunology       Date:  1976-04       Impact factor: 7.397

10.  Antiinflammatory effects of murine malignant cells.

Authors:  R M Fauve; B Hevin; H Jacob; J A Gaillard; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

View more
  7 in total

1.  Tumor-reactive IgE antibodies in plasma of patients with gastrointestinal carcinomas.

Authors:  I Berczi; V Holford-Strevens; Z H Warsi; L S McMorris; R H Thorlakson; T K Thorlakson; A H Sehon
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Blood histamine and solid malignant tumors.

Authors:  C M Moriarty; J L Stucky; K W Hamburger; K D Patil; J F Foley; R R Koefoot
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Histamine levels in blood and other tissues of male and female C3H mice. II. Mice carrying a 3-methyl-cholanthrene-induced tumor [proceedings].

Authors:  P Scheinmann; B Lebel; N R Lynch; J C Salomon; J R Paupe; C Burtin
Journal:  Agents Actions       Date:  1979-04

4.  Increased tissue histamine in tumour-bearing mice and rats.

Authors:  C Burtin; P Scheinmann; J C Salomon; G Lespinats; C Frayssinet; B Lebel; P Canu
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

5.  Decreased blood histamine levels in patients with solid malignant tumours.

Authors:  C Burtin; C Noirot; J Paupe; P Scheinmann
Journal:  Br J Cancer       Date:  1983-03       Impact factor: 7.640

6.  Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors.

Authors:  C Burtin; P Scheinmann; J C Salomon; G Lespinats; P Canu
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

7.  Mechanism of inhibition of tumour growth by aspirin and indomethacin.

Authors:  N R Lynch; M Castes; M Astoin; J C Salomon
Journal:  Br J Cancer       Date:  1978-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.